Effect of paroxetine on neurological function and psychological state in patients with depression after acute ischemic stroke

Read full text Summarise with VIRAT
Authors: Feng-Feng Shen, Dong-Xiao Lin, Hua Li
Cited by: 0
References: 32

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND Failure to receive timely and effective treatment for post-acute ischemic stroke (post-AIS) depression will make treatment more difficult. Additionally, the effectiveness of current drug therapy needs to be optimized. AIM To examine the influences of paroxetine (PARX) on the neurological function and psychological well-being in post-AIS patients with depression. METHODS This study involved 106 patients with post-AIS depression admitted between May 2020 and May 2023. The participants included 52 in the control group (Con), who received sertraline, and 54 in the research group (Res), treated with PARX. The two groups were compared across several aspects: Neurological function (measured by the National Institutes of Health Stroke Scale), activities of daily living (assessed with the modified Barthel index), psychological status (evaluated using the Hamilton Anxiety Scale/Hamilton Depression Scales), serum biochemical markers (C-reactive protein; procalcitonin), clinical effectiveness, and the occurrence of adverse events. RESULTS The data showed significantly reduced scores on National Institutes of Health Stroke Scale, Hamilton Anxiety Scale, and Hamilton Depression Scale, as well as decreased levels of serum biochemical indices such as C-reactive protein and procalcitonin in the Res group after treatment, which were statistically lower than the baseline and compared to the Con group; the Res group also had a clearly higher total effective rate and modified Barthel index scores than the Con group, with a lower overall incidence of adverse events such as dry mouth, loss of appetite, headache, and insomnia. CONCLUSION In summary, PARX positively influences neurological function, activities of daily living, and psychological well-being in patients with post-AIS depression, warranting clinical attention.

Fields of Study & Subjects

Stroke Rehabilitation and Recovery Treatment of Major Depression Acute Ischemic Stroke Management

Publication details

Journal / source
World Journal of Psychiatry
Volume
16
Issue
4
Publication date
27 March 2026
Language
EN